Comparison of circulating total sFLT-1 to placental-specific sFLT-1 e15a in women with suspected preeclampsia

Soluble fms-like tyrosine kinase 1 (sFLT-1), a circulating anti-angiogenic factor that binds and antagonizes placental growth factor (PlGF), appears key to preeclamptic pathophysiology. Two main sFLT-1 splice variants exist: sFLT-1 e15a and sFLT-1 i13. Total sFLT-1/PlGF ratios are increasingly used...

Full description

Saved in:
Bibliographic Details
Published in:Placenta (Eastbourne) 2022-03, Vol.120, p.73-78
Main Authors: Rowson, S., Reddy, M., De Guingand, D.L., Langston-Cox, A., Marshall, S.A., da Silva Costa, F., Palmer, K.R.
Format: Article
Language:English
Subjects:
Biomarkers
Diagnosis
Early-onset preeclampsia
Female
Humans
Placenta - metabolism
Placenta Growth Factor
PLGF
Pre-Eclampsia - metabolism
Preeclampsia
Pregnancy
Receptor Protein-Tyrosine Kinases - metabolism
sFLT-1 splice variant
sFlt-1/PLGF ratio
Vascular Endothelial Growth Factor A - metabolism
Vascular Endothelial Growth Factor Receptor-1 - blood
Vascular Endothelial Growth Factor Receptor-1 - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soluble fms-like tyrosine kinase 1 (sFLT-1), a circulating anti-angiogenic factor that binds and antagonizes placental growth factor (PlGF), appears key to preeclamptic pathophysiology. Two main sFLT-1 splice variants exist: sFLT-1 e15a and sFLT-1 i13. Total sFLT-1/PlGF ratios are increasingly used clinically; we explore whether using placental-specific sFLT-1 e15a improves test performance compared with total sFLT-1 in preeclampsia diagnosis. Consent was obtained for serum sampling from 96 women with suspected preeclampsia. Total sFLT-1 and PlGF were quantified using the B.R.A.H.M.S Kryptor Compact Plus automated immunoassay platform, and sFLT-1 e15a by custom enzyme-linked immunosorbent assay. Test performance was then assessed by subsequent diagnosis. Of 96 participants, 32 did not develop preeclampsia, 32 had early-onset (
ISSN:0143-4004
1532-3102
DOI:10.1016/j.placenta.2022.02.017